Reportlinker Adds Kidney and Renal Diseases Therapeutics Market to 2017 - Strong Pipeline and Unmet Need Due to Poor Safety Profiles to Create Opportunities for Growth
NEW YORK, June 15, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Kidney and Renal Diseases Therapeutics Market to 2017 - Strong Pipeline and Unmet Need Due to Poor Safety Profiles to Create Opportunities for Growth
Summary
GBI Research's report, "Kidney and Renal Diseases Therapeutics Market to 2017 - Strong Pipeline and Unmet Need Due to Poor Safety Profiles and to Create Opportunities for Growth", provides in-depth analysis of unmet needs, drivers and barriers that impact the global kidney and renal diseases therapeutics market. The report analyzes the markets for kidney and renal diseases therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, prices and volumes are forecast until 2017 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.
Scope
The scope of this report includes -
- Annualized market data for the kidney and renal diseases therapeutics market from 2001 to 2010, forecast forward to 2017
- Analysis of the leading therapeutic segments.
- Analysis of the kidney and renal diseases therapeutics market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain, and Japan
- Market characterization of the kidney and renal diseases therapeutics market including market size, annual cost of therapy, and treatment usage patterns
- Key drivers and barriers that have a significant impact on the market
- Coverage of pipeline molecules in various phases of drug development
- Competitive benchmarking of leading companies.
- Key M&A activities, licensing agreements, that have taken place between 2008 and 2010 in the global kidney and renal diseases therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.
- Develop key strategic initiatives by understanding the key focus areas of leading companies.
- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.
Table of Contents
1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 6
1.2 List of Figures 8
2 Introduction 10
2.1 GBI Research Report Guidance 11
3 Kidney and Renal Diseases Therapeutics Market to 2017: Market Overview 12
3.1 Introduction 12
3.2 Revenue Forecasts for the Global Kidney and Renal Disease Market 13
3.2.1 Revenue 13
3.2.2 Annual Cost of Treatment (ACT) 14
3.3 Treatment Usage Patterns 15
3.3.1 Diseased Population 17
3.3.2 Treatment Seeking Population 18
3.3.3 Diagnosis Population 19
3.3.4 Prescription Population 20
4 Kidney and Renal Diseases Therapeutics Market to 2017: Geographical Landscape 21
4.1 Revenue Analysis by Geography 21
4.2 The US 23
4.2.1 Revenue 23
4.2.2 Annual Cost of Treatment 24
4.3 Top Five Countries of Europe 25
4.3.1 Revenue 25
4.3.2 Annual Cost of Treatment 26
4.4 Japan 27
4.4.1 Revenue 27
4.4.2 Annual Cost of Treatment 28
5 Kidney and Renal Diseases Therapeutics Market to 2017: Therapeutic Landscape 29
5.1 Chronic Kidney Diseases Market 29
5.1.1 Introduction 29
5.1.2 Revenue 30
5.1.3 Annual Cost of Treatment 32
5.1.4 Treatment Usage Patterns 33
5.1.5 Drivers and Barriers for the Chronic Kidney Diseases Market 39
5.1.6 Drivers for the Chronic Kidney Disease Market 39
5.1.7 Barriers for the Chronic Kidney Disease Market 39
5.2 Renal Anemia Market 40
5.2.1 Introduction 40
5.2.2 Revenue 40
5.2.3 Annual Cost of Treatment 43
5.2.4 Treatment Usage Patterns 44
5.2.5 Drivers and Barriers for the Renal Anemia Market 50
5.2.6 Drivers for the Renal Anemia Market 51
5.2.7 Barriers for the Renal Anemia Market 51
5.3 Diabetic Nephropathy Market 52
5.3.1 Introduction 52
5.3.2 Revenue 52
5.3.3 Annual Cost of Treatment 55
5.3.4 Treatment Usage Patterns 56
5.3.5 Drivers and Barriers for the Diabetic Nephropathy Market 61
5.3.6 Drivers for the Diabetic Nephropathy Market 61
5.3.7 Barriers for the Diabetic Nephropathy Market 61
5.4 Acute Kidney Injury Market 62
5.4.1 Introduction 62
5.4.2 Revenue 63
5.4.3 Annual Cost of Treatment 65
5.4.4 Treatment Usage Patterns 67
5.4.5 Drivers and Barriers for the Acute Kidney Injury Market 73
5.4.6 Drivers for the Acute Kidney Injury Market 73
5.4.7 Barriers for the Acute Kidney Injury Nephropathy Market 73
6 Kidney and Renal Diseases Therapeutics Market to 2017 – Product Pipeline Analysis 74
6.1 Introduction 74
6.1.1 Research and Development Pipeline – Chronic Kidney Disease (CKD) 75
6.1.2 Research and Development Pipeline – Renal Anemia (RA) 81
6.1.3 Research and Development Pipeline – Diabetic Nephropathy (DN) 83
6.1.4 Research and Development Pipeline – Acute Kidney Injury (AKI) 86
6.2 Profiles of Promising Drugs in the Kidney and Renal Disease Market 89
6.2.1 AMG 223 89
6.2.2 AST-120 90
6.2.3 CellCept 90
6.2.4 Ferinject 91
6.2.5 Genz-644470 92
6.2.6 Hematide 93
6.2.7 HEPLISAV 93
6.2.8 Heptar 94
6.2.9 SBR759 95
6.2.10 Sulodexide 96
6.2.11 YM533 96
6.2.12 Zuragen 97
6.2.13 Olmetec 97
7 Kidney and Renal Diseases Therapeutics Market to 2017 – Competitive Landscape 99
7.1 Market Share Analysis 99
7.2 Amgen Inc. 100
7.2.1 Company Overview 100
7.2.2 Business Overview 100
7.2.3 SWOT Analysis 101
7.3 Merck & Co., Inc. 102
7.3.1 Company Overview 102
7.3.2 Business Overview 102
7.3.3 SWOT Analysis 103
7.4 Bristol-Myers Squibb Company 104
7.4.1 Company Overview 104
7.4.2 Business Overview 104
7.4.3 SWOT Analysis 105
7.5 Hoffmann-La Roche Inc. 106
7.5.1 Company Overview 106
7.5.2 Business Overview 106
7.5.3 SWOT Analysis 107
7.6 Shire Inc. 108
7.6.1 Company Overview 108
7.6.2 Business Overview 108
7.6.3 SWOT Analysis 109
8 Kidney and Renal Diseases Therapeutics Market to 2017 – M&A Landscape 110
8.1 M&A Deals 110
8.1.1 Deal Summary 111
8.1.2 Deals by Geography 113
8.2 Licensing Deals 114
8.2.1 Summary of Licensing Deals (2009-2010) 115
8.3 Co-development Deals 117
8.3.1 Summary of Co-development Deals (2009-2010) 118
9 Kidney and Renal Diseases Therapeutics Market to 2017 – Appendix 120
9.1 Market Definitions 120
9.2 Abbreviations 120
9.3 Research Methodology 121
9.3.1 Coverage 121
9.3.2 Secondary Research 122
9.3.3 Primary Research 122
9.3.4 Expert Panel Validation 124
9.4 Contact Us 124
9.5 Disclaimer 124
9.6 Sources 124
List of Tables
1.1 List of Tables
Table 1: Kidney and Renal Diseases Therapeutics Market, Global, Revenue Forecasts ($bn), 2002-2010 13
Table 2: Kidney and Renal Diseases Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2017 13
Table 3: Kidney and Renal Diseases Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010 14
Table 4: Kidney and Renal Diseases Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2017 14
Table 5: Kidney and Renal Diseases Therapeutics Market, Global, Treatment Usage Pattern (millions), 2002-2010 16
Table 6: Kidney and Renal Diseases Therapeutics Market, Global, Treatment Usage Pattern (millions), 2010-2017 16
Table 7: Kidney and Renal Diseases Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2010 21
Table 8: Kidney and Renal Diseases Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2010-2017 22
Table 9: Kidney and Renal Diseases Therapeutics Market, The US, Revenue Forecasts ($bn), 2002-2010 23
Table 10: Kidney and Renal Diseases Therapeutics Market, The US, Revenue Forecasts ($bn), 2010-2017 23
Table 11: Kidney and Renal Diseases Therapeutics Market, The US, Annual Cost of Treatment ($), 2002-2010 24
Table 12: Kidney and Renal Diseases Therapeutics Market, The US, Annual Cost of Treatment ($), 2010-2017 24
Table 13: Kidney and Renal Diseases Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts ($bn), 2002-2010 25
Table 14: Kidney and Renal Diseases Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts ($bn), 2010-2017 25
Table 15: Kidney and Renal Diseases Therapeutics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2002-2010 26
Table 16: Kidney and Renal Diseases Therapeutics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2010-2017 26
Table 17: Kidney and Renal Diseases Therapeutics Market, Japan, Revenue Forecasts ($bn), 2002-2010 27
Table 18: Kidney and Renal Diseases Therapeutics Market, Japan, Revenue Forecasts ($bn), 2010-2017 27
Table 19: Kidney and Renal Diseases Therapeutics Market, Japan, Annual Cost of Treatment ($), 2002-2010 28
Table 20: Kidney and Renal Diseases Therapeutics Market, Japan, Annual Cost of Treatment ($), 2010-2017 28
Table 21: Kidney and Renal Diseases Therapeutics Market, Chronic Kidney Disease, Global Revenue Forecasts ($bn), 2002-2010 30
Table 22: Kidney and Renal Diseases Therapeutics Market, Chronic Kidney Disease, Global Revenue Forecasts ($bn), 2010-2017 30
Table 23: Kidney and Renal Diseases Therapeutics Market, Chronic Kidney Disease, Revenue by Geography ($bn), 2002-2010 31
Table 24: Kidney and Renal Diseases Therapeutics Market, Chronic Kidney Disease, Revenue by Geography ($bn), 2010-2017 31
Table 25: Kidney and Renal Diseases Therapeutics Market, Chronic Kidney Disease, Annual Cost of Treatment by Geography ($), 2002-2010 32
Table 26: Kidney and Renal Diseases Therapeutics Market, Chronic Kidney Disease, Annual Cost of Treatment by Geography ($), 2010-2017 32
Table 27: Kidney and Renal Diseases Therapeutics Market, Chronic Kidney Disease, Global Treatment Usage Pattern (millions), 2002-2010 33
Table 28: Kidney and Renal Diseases Therapeutics Market, Chronic Kidney Disease, Global Treatment Usage Pattern (millions), 2010-2017 34
Table 29: Kidney and Renal Diseases Therapeutics Market, Renal Anemia, Global Revenue Forecasts ($bn), 2002-2010 41
Table 30: Kidney and Renal Diseases Therapeutics Market, Renal Anemia, Global Revenue Forecasts ($bn), 2010-2017 41
Table 31: Kidney and Renal Diseases Therapeutics Market, Renal Anemia, Revenue by Geography ($bn), 2002-2010 42
Table 32: Kidney and Renal Diseases Therapeutics Market, Renal Anemia, Revenue by Geography ($bn), 2010-2017 42
Table 33: Kidney and Renal Diseases Therapeutics Market, Renal Anemia, Annual Cost of Treatment by Geography ($), 2002-2010 43
Table 34: Kidney and Renal Diseases Therapeutics Market, Renal Anemia, Annual Cost of Treatment by Geography ($), 2010-2017 44
Table 35: Kidney and Renal Diseases Therapeutics Market, Renal Anemia, Global Treatment Usage Pattern (millions), 2002-2010 45
Table 36: Kidney and Renal Diseases Therapeutics Market, Renal Anemia, Global Treatment Usage Pattern (millions), 2010-2017 45
Table 37: Kidney and Renal Diseases Therapeutics Market, Diabetic Nephropathy, Global Revenue Forecasts ($bn), 2002-2010 53
Table 38: Kidney and Renal Diseases Therapeutics Market, Diabetic Nephropathy, Global Revenue Forecasts ($bn), 2010-2017 53
Table 39: Kidney and Renal Diseases Therapeutics Market, Diabetic Nephropathy, Revenue by Geography ($bn), 2002-2010 54
Table 40: Kidney and Renal Diseases Therapeutics Market, Diabetic Nephropathy, Revenue by Geography ($bn), 2010-2017 54
Table 41: Kidney and Renal Diseases Therapeutics Market, Diabetic Nephropathy, Annual Cost of Treatment by Geography ($), 2002-2010 55
Table 42: Kidney and Renal Diseases Therapeutics Market, Diabetic Nephropathy, Annual Cost of Treatment by Geography ($), 2010-2017 55
Table 43: Kidney and Renal Diseases Therapeutics Market, Diabetic Nephropathy, Global Treatment Usage Pattern (millions), 2002-2010 56
Table 44: Kidney and Renal Diseases Therapeutics Market, Diabetic Nephropathy, Global Treatment Usage Pattern (millions), 2010-2017 57
Table 45: Kidney and Renal Diseases Therapeutics Market, Acute Kidney Injury, Global Revenue Forecasts ($bn), 2002-2010 63
Table 46: Kidney and Renal Diseases Therapeutics Market, Acute Kidney Injury, Global Revenue Forecasts ($bn), 2010-2017 63
Table 47: Kidney and Renal Diseases Therapeutics Market, Acute Kidney Injury, Revenue by Geography ($bn), 2002-2010 64
Table 48: Kidney and Renal Diseases Therapeutics Market, Acute Kidney Injury, Revenue by Geography ($bn), 2010-2017 65
Table 49: Kidney and Renal Diseases Therapeutics Market, Acute Kidney Injury, Annual Cost of Treatment by Geography ($), 2002-2010 66
Table 50: Kidney and Renal Diseases Therapeutics Market, Acute Kidney Injury, Annual Cost of Treatment by Geography ($), 2010-2017 66
Table 51: Kidney and Renal Diseases Therapeutics Market, Acute Kidney Injury, Global Treatment Usage Pattern (millions), 2002-2010 68
Table 52: Kidney and Renal Diseases Therapeutics Market, Acute Kidney Injury, Global Treatment Usage Pattern (millions), 2010-2017 68
Table 53: Research and Development Pipeline – Chronic Kidney Disease (CKD) - 2011 76
Table 54: Research and Development Pipeline – Renal Anemia (RA) - 2011 82
Table 55: Research and Development Pipeline – Diabetic Nephropathy (DN) - 2011 84
Table 56: Research and Development Pipeline – Acute Kidney Injury (AKI) - 2011 87
Table 57: Kidney and Renal Diseases Therapeutics Market, Global Major M&A Deals, 2004-2010 110
Table 58: Kidney and Renal Diseases Therapeutics Market, Global Licensing Deals, 2004-2010 114
Table 59: Kidney and Renal Diseases Therapeutics Market, Global Major Co-development Deals, 2004-2010 117
List of Figures
1.2 List of Figures
Figure 1: Kidney and Renal Diseases Therapeutics Market, Global, Revenue Forecasts ($bn), 2002-2017 13
Figure 2: Kidney and Renal Diseases Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017 14
Figure 3: Kidney and Renal Diseases Therapeutics Market, Global, Treatment Usage Pattern (millions), 2002-2017 15
Figure 4: Kidney and Renal Diseases Therapeutics Market, Global, Diseased Population (millions), 2002-2017 17
Figure 5: Kidney and Renal Diseases Therapeutics Market, Global, Treatment Seeking Population (millions), 2002-2017 18
Figure 6: Kidney and Renal Diseases Therapeutics Market, Global, Diagnosed Population (millions), 2002-2017 19
Figure 7: Kidney and Renal Diseases Therapeutics Market, Global, Prescription Population (millions), 2002-2017 20
Figure 8: Kidney and Renal Diseases Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2017 21
Figure 9: Kidney and Renal Diseases Therapeutics Market, The US, Revenue Forecasts ($bn), 2002-2017 23
Figure 10: Kidney and Renal Diseases Therapeutics Market, The US, Annual Cost of Treatment ($), 2002-2017 24
Figure 11: Kidney and Renal Diseases Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts ($bn), 2002-2017 25
Figure 12: Kidney and Renal Diseases Therapeutics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2002-2017 26
Figure 13: Kidney and Renal Diseases Therapeutics Market, Japan, Revenue Forecasts ($bn), 2002-2017 27
Figure 14: Kidney and Renal Diseases Therapeutics Market, Japan, Annual Cost of Treatment ($), 2002-2017 28
Figure 15: Kidney and Renal Diseases Therapeutics Market, Chronic Kidney Disease, Global Revenue Forecasts ($bn), 2002-2017 30
Figure 16: Kidney and Renal Diseases Therapeutics Market, Chronic Kidney Disease, Revenue by Geography ($bn), 2002-2017 31
Figure 17: Kidney and Renal Diseases Therapeutics Market, Chronic Kidney Disease, Annual Cost of Treatment by Geography ($), 2002-2017 32
Figure 18: Kidney and Renal Diseases Therapeutics Market, Chronic Kidney Disease, Global Treatment Usage Pattern (millions), 2002-2017 33
Figure 19: Kidney and Renal Diseases Therapeutics Market, Chronic Kidney Disease, Global Diseased Population (millions), 2002-2017 35
Figure 20: Kidney and Renal Diseases Therapeutics Market, Chronic Kidney Disease, Global Treatment Seeking Population (millions), 2002-2017 36
Figure 21: Kidney and Renal Diseases Therapeutics Market, Chronic Kidney Disease, Global Diagnosed Population (millions), 2002-2017 37
Figure 22: Kidney and Renal Diseases Therapeutics Market, Chronic Kidney Disease, Global Prescription Population (millions), 2002-2017 38
Figure 23: Kidney and Renal Diseases Therapeutics Market, Chronic Kidney Diseases, Global Market Drivers and Barriers, 2010-2017 39
Figure 24: Kidney and Renal Diseases Therapeutics Market, Renal Anemia, Global Revenue Forecasts ($bn), 2002-2017 41
Figure 25: Kidney and Renal Diseases Therapeutics Market, Renal Anemia, Revenue by Geography ($bn), 2002-2017 42
Figure 26: Kidney and Renal Diseases Therapeutics Market, Renal Anemia, Annual Cost of Treatment by Geography ($), 2002-2017 43
Figure 27: Kidney and Renal Diseases Therapeutics Market, Renal Anemia, Global Treatment Usage Pattern (millions), 2002-2017 44
Figure 28: Kidney and Renal Diseases Therapeutics Market, Renal Anemia, Global Diseased Population (millions), 2002-2017 46
Figure 29: Kidney and Renal Diseases Therapeutics Market, Renal Anemia, Global Treatment Seeking Population (millions), 2002-2017 47
Figure 30: Kidney and Renal Diseases Therapeutics Market, Renal Anemia, Global Diagnosed Population (millions), 2002-2017 48
Figure 31: Kidney and Renal Diseases Therapeutics Market, Renal Anemia, Global Prescription Population (millions), 2002-2017 49
Figure 32: Kidney and Renal Diseases Therapeutics Market, Renal Anemia, Global Market Drivers and Barriers, 2010-2017 50
Figure 33: Kidney and Renal Diseases Therapeutics Market, Diabetic Nephropathy, Global Revenue Forecasts ($bn), 2002-2017 52
Figure 34: Kidney and Renal Diseases Therapeutics Market, Diabetic Nephropathy, Revenue by Geography ($bn), 2002-2017 54
Figure 35: Kidney and Renal Diseases Therapeutics Market, Diabetic Nephropathy, Annual Cost of Treatment by Geography ($), 2002-2017 55
Figure 36: Kidney and Renal Diseases Therapeutics Market, Diabetic Nephropathy, Global Treatment Usage Pattern (millions), 2002-2017 56
Figure 37: Kidney and Renal Diseases Therapeutics Market, Diabetic Nephropathy, Global Diseased Population (millions), 2002-2017 57
Figure 38: Kidney and Renal Diseases Therapeutics Market, Diabetic Nephropathy, Global Treatment Seeking Population (millions), 2002-2017 58
Figure 39: Kidney and Renal Diseases Therapeutics Market, Diabetic Nephropathy, Global Diagnosed Population (millions), 2002-2017 59
Figure 40: Kidney and Renal Diseases Therapeutics Market, Diabetic Nephropathy, Global Prescription Population (millions), 2002-2017 60
Figure 41: Kidney and Renal Diseases Therapeutics Market, Diabetic Nephropathy, Global Market Drivers and Barriers, 2010-2017 61
Figure 42: Kidney and Renal Diseases Therapeutics Market, Acute Kidney Injury, Global Revenue Forecasts ($bn), 2002-2017 63
Figure 43: Kidney and Renal Diseases Therapeutics Market, Acute Kidney Injury, Revenue by Geography ($bn), 2002-2017 64
Figure 44: Kidney and Renal Diseases Therapeutics Market, Acute Kidney Injury, Annual Cost of Treatment by Geography ($), 2002-2017 65
Figure 45: Kidney and Renal Diseases Therapeutics Market, Acute Kidney Injury, Global Treatment Usage Pattern (millions), 2002-2017 67
Figure 46: Kidney and Renal Diseases Therapeutics Market, Acute Kidney Injury, Global Diseased Population (millions), 2002-2017 69
Figure 47: Kidney and Renal Diseases Therapeutics Market, Acute Kidney Injury, Global Treatment Seeking Population (millions), 2002-2017 70
Figure 48: Kidney and Renal Diseases Therapeutics Market, Acute Kidney Injury, Global Diagnosed Population (millions), 2002-2017 71
Figure 49: Kidney and Renal Diseases Therapeutics Market, Acute Kidney Injury, Global Prescription Population (millions), 2002-2017 72
Figure 50: Kidney and Renal Diseases Therapeutics Market, Acute Kidney Injury, Global Market Drivers and Barriers, 2010-2017 73
Figure 51: Kidney and Renal Diseases Therapeutics Market, Global Product Pipeline by Phase (%), 2011 74
Figure 52: Research and Development Pipeline – Chronic Kidney Disease (CKD) - 2011 75
Figure 53: Research and Development Pipeline – Renal Anemia (RA) – 2011 81
Figure 54: Research and Development Pipeline – Diabetic Nephropathy (DN) - 2011 83
Figure 55: Research and Development Pipeline – Acute Kidney Injury (AKI) – 2011 86
Figure 56: Kidney and Renal Diseases Therapeutics Market, Global, Top Companies Share (%), 2009 99
Figure 57: SWOT Analysis of Amgen Inc. 101
Figure 58: SWOT Analysis of Merck & Co., Inc. 103
Figure 59: SWOT Analysis of Bristol-Myers Squibb Company 105
Figure 60: SWOT Analysis of Roche 107
Figure 61: SWOT Analysis of Shire 109
Figure 62: Kidney and Renal Diseases Therapeutics Market, Global, Major M&A Deals by Geography, 2005-2010 113
Figure 63: Kidney and Renal Diseases Therapeutics Market, Global, Major Licensing Deals by Geography, 2005-2010 115
Figure 64: GBI Research Market Forecasting Model 123
Companies Mentioned
Amgen Inc.
Merck & Co., Inc.
Bristol-Myers Squibb Company
Hoffmann-La Roche Inc.
Shire Inc.
To order this report:
Pathology Industry: Kidney and Renal Diseases Therapeutics Market to 2017 - Strong Pipeline and Unmet Need Due to Poor Safety Profiles to Create Opportunities for Growth
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article